Compounded Semaglutide: Cost, Dosing, and Sourcing Guide (2026)

Compounded semaglutide became one of the most searched peptide topics of the past two years -- first because Ozempic and Wegovy shortages made branded supply unreliable, then because the price difference between brand and compounded versions became too large for most researchers and clinicians to ignore. Brand Ozempic lists at $850 to $1,000 per month without insurance. Compounded semaglutide from a 503B outsourcing facility typically runs $200 to $400. Research-grade semaglutide from a reputable peptide vendor runs lower still.

This guide covers what compounded semaglutide actually is, how it differs from the brand product, what dosing protocols look like, what quality markers matter when evaluating a source, and how researchers should think about the landscape in 2026.

What Is Compounded Semaglutide?

Semaglutide is a GLP-1 receptor agonist peptide. Its full sequence is a 31-amino-acid analog of native glucagon-like peptide-1, modified to extend half-life to approximately one week through acylation and amino acid substitutions. Novo Nordisk holds the brand patents for Ozempic (diabetes indication) and Wegovy (obesity indication), both at the same active molecule.

Compounded semaglutide refers to semaglutide prepared outside of Novo Nordisk's manufacturing process. There are three main categories:

• 503B outsourcing facilities: FDA-registered facilities that produce sterile compounded drugs at scale. They operate under cGMP standards and are subject to FDA inspection. The highest quality tier of compounded pharmaceutical product. Required to produce sterility and endotoxin testing data per batch.
• 503A compounding pharmacies: Traditional compounding pharmacies that fill individual prescriptions. Less rigorous FDA oversight than 503B. Quality varies considerably between pharmacies. Legally require a valid prescription.
• Research peptide vendors: Sell semaglutide as a research chemical for laboratory use. Not for human administration. Regulated differently from pharmaceutical compounders -- no prescription required, sold as a research compound. Quality ranges from excellent to poor depending on the vendor; third-party COA is the minimum bar.

Compounded Semaglutide vs Brand: What Is and Is Not the Same

Standard Dosing Protocols

The FDA-approved titration schedules for Ozempic and Wegovy are the most widely referenced protocols because they were validated in large-scale trials with tens of thousands of participants. Research protocols generally follow similar escalation logic to manage GI side effects.

Ozempic Titration (Diabetes Indication)

Wegovy Titration (Weight Loss Indication)

The STEP 1 trial -- the pivotal weight loss trial for semaglutide -- showed 14.9% average weight reduction at 68 weeks at the 2.4 mg dose versus 2.4% in the placebo group. Roughly 86% of participants achieved at least 5% body weight loss and 69% achieved at least 10%. These are the benchmark numbers for GLP-1 weight loss research. See the full semaglutide dosage guide for extended protocol details.

What Compounded Semaglutide Is Typically Sold As

Research peptide vendors sell semaglutide in two forms:

• Lyophilized powder: Freeze-dried, typically 2 mg or 5 mg per vial. Requires reconstitution with bacteriostatic water before use. More stable for shipping and long-term storage. See the peptide reconstitution guide for step-by-step instructions.
• Pre-mixed solution: Already dissolved in bacteriostatic water or sodium chloride, typically at 2 mg/mL or 5 mg/mL concentration. Convenient but slightly more fragile in transit. Requires refrigeration.

A 10 mL vial at 5 mg/mL contains 50 mg total semaglutide. At a 2.4 mg weekly dose that is approximately 20 weeks of supply from a single vial. At initiation doses (0.25 mg/week) it extends considerably further. Most researchers working through a full titration cycle use one 10 mL vial across the first 12 to 16 weeks.

How to Evaluate a Compounded Semaglutide Source

Quality in the research peptide space is not uniform. The following markers separate credible vendors from unreliable ones:

Third-Party COA

A certificate of analysis from an independent testing laboratory is non-negotiable. The COA should show:

• Purity by HPLC: reputable vendors show 98% or higher
• Molecular weight confirmation (semaglutide: 4113.58 g/mol)
• Peptide identity by mass spectrometry
• Batch number that matches the product shipped

COAs should be batch-specific, not a single document applied to all products. Avoid vendors whose COA cannot be matched to the specific vial purchased.

Reconstitution and Storage Specs

Lyophilized semaglutide should be stored at -20C before reconstitution and used within 28 days of mixing when refrigerated at 4C. Vendors that publish clear storage specs are demonstrating product knowledge; those that do not are a yellow flag.

Salt Form Disclosure

Some research vendors sell semaglutide acetate; others sell the free base or a sodium salt form. The acetate form is the most common and what most dosing calculations are based on. Verify the salt form before using any dosing reference.

Side Effects and What the Data Shows

The side effect profile for semaglutide is well-documented across the STEP trial program and the real-world Ozempic/Wegovy post-marketing data. The most common effects are GI-related and typically dose-dependent:

• Nausea: Most common at initiation and dose escalation. Reported in 44% of Wegovy participants vs 16% placebo in STEP 1. Usually resolves within 4 to 8 weeks at any given dose level.
• Vomiting: 24% in Wegovy group vs 6% placebo in STEP 1.
• Diarrhea: 30% vs 16% placebo.
• Constipation: 24% vs 11% placebo.
• Reduced appetite / early satiety: The primary mechanism of action for weight loss; often described as the drug "working" rather than a side effect per se.

GI side effects are the primary reason for the slow titration schedule. Moving from 0.25 mg to 2.4 mg over 16 to 20 weeks dramatically reduces tolerability issues compared to fast escalation. Discontinuation for adverse events in the STEP trials was approximately 7% in the semaglutide group, compared to roughly 3% in placebo.

Less common but more serious signals from post-marketing data include pancreatitis, gallbladder disease, and thyroid C-cell concerns (flagged in animal studies; not confirmed in humans but included in the FDA black box warning for the product class). Any research application should account for these considerations.

Compounded Semaglutide and the FDA: The 2024 to 2026 Landscape

The FDA designated semaglutide as a drug in shortage in 2022, which temporarily expanded the legal basis for 503A and 503B compounding. As supply normalized through 2024 and 2025, the FDA issued guidance narrowing which compounders could continue producing semaglutide and under what circumstances. The rules shifted several times.

As of mid-2026, the core legal framework looks like this:

• 503B outsourcing facilities may produce compounded semaglutide only for patients who have a documented clinical need that the commercially available product cannot meet (e.g., specific dose combinations not available in the branded auto-injector).
• 503A pharmacies operate under state pharmacy board oversight and the details vary by state. Many still compound semaglutide for individual prescriptions.
• Research peptide vendors operate outside the pharmaceutical compounding framework and sell for non-human research use. This regulatory category was not directly affected by the shortage designation changes.

Researchers sourcing semaglutide for laboratory purposes should track the FDA's compounding guidance pages for updates, as this area has seen more enforcement activity than most peptide categories.

How Compounded Semaglutide Compares to Other GLP-1 Options

Semaglutide is not the only GLP-1 research option available. The broader landscape for 2026:

For a direct comparison of the first two approved compounds, see the semaglutide vs tirzepatide guide. For context on the cost side of brand products, the semaglutide cost breakdown covers out-of-pocket pricing in more detail.

Sourcing Semaglutide for Research: What Matters

For laboratory research applications, the two vendor benchmarks that matter above all others are purity documentation and peptide form clarity. A 98% pure semaglutide at the correct molecular weight with a batch-matched COA from an independent lab is a meaningfully different product from a vendor that provides a generic COA or no purity data at all.

Pantheon and Amino Club have both been referenced consistently in peptide research communities for meeting this bar -- batch-specific HPLC data, mass spec confirmation, and clear reconstitution specs. Both carry semaglutide in lyophilized and pre-mixed forms.